Evidence map›Paper›PMID 36707385›Full record

ArticleHuman immunology2023

The role of the HLA allelic repertoire on the clinical severity of COVID-19 in Canadians, living in the Saskatchewan province.

Pramath Kakodkar, Pouneh Dokouhaki, Fang Wu, Jay Shavadia, Revathi Nair, Destinie Webster, Terry Sawyer, Tao Huan, Ahmed Mostafa

Open access · greenAbstract read
In one paragraph

Article in Human immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Pramath KakodkarDepartment of Pathology and Laboratory Medicine, University of Saskatchewan College of Medicine, Canada. Electronic address: pramath.kakodkar@saskhealthauthority.ca.
Pouneh DokouhakiDepartment of Pathology and Laboratory Medicine, University of Saskatchewan College of Medicine, Canada. Electronic address: pouneh.dokouhaki@saskhealthauthority.ca.
Fang WuDepartment of Pathology and Laboratory Medicine, University of Saskatchewan College of Medicine, Canada. Electronic address: fang.wu@saskhealthauthority.ca.
Jay ShavadiaDivision of Cardiology, Department of Medicine, University of Saskatchewan, Canada. Electronic address: Jay.Shavadia@saskhealthauthority.ca.
Revathi NairCollege of Medicine, University of Saskatchewan, Canada. Electronic address: revathi.nair@saskhealthauthority.ca.
Destinie WebsterDepartment of Pathology and Laboratory Medicine, University of Saskatchewan College of Medicine, Canada. Electronic address: Destinie.Webster@saskhealthauthority.ca.
Terry SawyerDepartment of Pathology and Laboratory Medicine, University of Saskatchewan College of Medicine, Canada. Electronic address: Terry.Sawyer@saskhealthauthority.ca.
Tao HuanDepartment of Chemistry, University of British Columbia, Canada. Electronic address: thuan@chem.ubc.ca.
Ahmed MostafaDepartment of Pathology and Laboratory Medicine, University of Saskatchewan College of Medicine, Canada. Electronic address: ahmed.mostafa@saskhealthauthority.ca.
University of Saskatchewan · CASaskatchewan Health · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe HLA system has been implicated as an underlying determinant for modulating the immune response to SARS-CoV-2. In this study, we aimed to determine the association of patients' HLA genetic profiles with the disease severity of COVID-19 infection.

methodsProspective study was conducted on COVID-19 patients (n = 40) admitted to hospitals in Saskatoon, Canada, between March and December 2020. Next-generation sequencing was performed on the patient samples to obtain high-resolution HLA typing profiles. The statistical association between HLA allelic frequency and disease severity was examined. The disease severity was categorized based on the length of hospital stay and intensive care needs or demise during the hospital stay.

resultsHLA allelic frequencies of the high and low-severity cohorts were normalized against corresponding background allelic frequencies. In the high-severity cohort, A*02:06 (11.8-fold), B*51:01 (2.4-fold), B*15:01(3.1-fold), C*01:02 (3.3-fold), DRB1*08:02 (31.2-fold), DQ*06:09 (11-fold), and DPB1*04:02(4-fold) were significantly overrepresented (p < 0.05) making these deleterious alleles. In the low-severity cohort, A*24:02 (2.8-fold), B*35:01 (2.8-fold), DRB1*04:07 (5.3-fold), and DRB1*08:11 (22-fold) were found to be significantly overrepresented (p < 0.05) making these protective alleles. These above alleles interact with NK cell antiviral activity via the killer immunoglobulin-like receptors (KIR). The high-severity cohort had a higher predilection for HLA alleles associated with KIR subgroups; Bw4-80I (1.1-fold), and C1 (1.6-fold) which promotes NK cell inhibition, while the low-severity cohort had a higher predilection for Bw4-80T (1.6-fold), and C2 (1.6-fold) which promote NK cell activation.

conclusionIn this study, the HLA allelic repository with the distribution of deleterious and protective alleles was found to correlate with the severity of the clinical course in COVID-19. Moreover, the interaction of specific HLA alleles with the KIR-associated subfamily modulates the NK cell-mediated surveillance of SARS-CoV-2. Both deleterious HLA alleles and inhibitory KIR appear prominently in the severe COVID-19 group focusing on the importance of NK cells in the convalescence of COVID-19.

Indexed as

COVID-19HLA AntigensAllelesHumansProspective StudiesReceptors, KIRSARS-CoV-2SaskatchewanHLA AntigensReceptors, KIRCOVID-19HLA typingKiller cell immunoglobulin-like receptorsKIRNatural killer cells

Identifiers

PMID36707385
PMCPMC9852320
OpenAlexW4318391080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.